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ABSTRACT
The role of NFAT family transcription factors in erythropoiesis is so far unknown, 
although their involvement has been suggested previously. We have shown recently 
that Il2-/- mice develop severe anemia due to defects in KLF1 activity during BM 
erythropoiesis. Although, KLF1 activity is indispensable for erythropoiesis, the 
molecular details of Klf1 expression have not yet been elucidated. Here we show that 
an enhanced NFATc1 activity induced by increased integrin-cAMP signaling plays a 
critical role in the dysregulation of Klf1 expression and thereby cause anemia in Il2-
/- mice. Interestingly, enhanced NFATc1 activity augmented apoptosis of immature 
erythrocytes in Il2-/- mice. On the other hand, ablation of NFATc1 activity enhanced 
differentiation of Ter119+ cells in BM. Restoring IL-2 signaling in Il2-/- mice reversed 
the increase in cAMP-NFAT signaling and facilitated normal erythropoiesis. Altogether, 
our study identified an NFAT-mediated negative signaling axis, manipulation of which 
could facilitate erythropoiesis and prevent anemia development.
INTRODUCTION
Erythropoiesis in bone marrow (BM) is regulated 
by a host of signaling pathways [1–4], and key erythroid 
lineage-specific transcription factors (TF) such as the 
erythroid Krüppel-like factor (EKLF/KLF1), GATA1, 
RUNX1, FOG1, SCL and NF-E2 etc., [1, 2, 5–7]. 
Additionally, growth factors such as erythropoietin (Epo) 
play an indispensable role in facilitating differentiation of 
immature erythrocytes to become mature red blood cells 
(RBC) [8]. Genetic ablation or inactivating mutations in 
any of these molecules have been reported to be lethal for 
the survival of animals as these abnormalities result in 
severely defective erythropoiesis [9–15].
IL-2 signaling plays a critical role in the survival, 
proliferation and function of a variety of immune cells 
[16–18]. Also, it is a critical factor in maintaining immune 
homeostasis because of its influence on regulatory T (Treg) 
cells [19]. Il2−/− and all other mice with defective IL-2 
signaling develop severe autoimmune pathologies due to 
lack of optimal Treg cell activity [20–23]. Severe immune 
pathologies have also been reported in case of humans 
having defects in IL-2 signaling [24]. We have recently 
shown that mice lacking IL-2 signaling have strong 
defects in erythrocyte differentiation and they develop 
anemia very early in life [25]. Though, the reasons behind 
this are not completely known, we have reported that Klf1 
suppression is a major factor for anemia development 
in Il2−/− mice [25]. However, in addition to dysregulated 
KLF1 activity, whether other signaling molecules are 
also involved is so far unknown. Further, the molecular 
mechanism involved in Klf1 suppression in IL-2-deficient 
erythroid precursor cells has also not been elucidated.
Although, many TFs are involved in the regulation 
of BM erythropoiesis, the contributions of nuclear factor 
of activated T cell (NFAT) family TFs (NFATc1, NFATc2, 
NFATc3, NFATc4 and NFAT5) has so far not been 
investigated. Besides NFAT5, all other NFAT proteins 
are regulated by a calcium (Ca2+)-calcineurin-mediated 
mechanism [26, 27]. In mature lymphocytes, immune 
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receptor (T cell receptor; TCR or B cell receptors; BCR) 
ligation with cognate ligands results in an increase in 
intracellular calcium levels in a phospholipase C-γ 
(PLC-γ)-dependent manner, which subsequently activate 
the serine-threonine phosphatase calcineurin. Active 
calcineurin dephosphorylates multiple serine residues in 
the cytoplasmic NFAT proteins facilitating their activation 
and nuclear translocation. Nuclear NFAT regulates gene 
expression related to cytokine production, cell cycle, cell 
death, and cell differentiation etc, [28, 29]. Besides the 
calcineurin-mediated pathway, NFAT proteins can also be 
activated by cytokines as has been reported in the context 
of preTCR-negative thymocytes [30]. On the other hand, 
NFAT5 mostly expressed in non-hematopoietic lineage 
cells is activated upon osmotic stress [31]. Alterations in 
NFAT activity have been reported to induce pathological 
conditions ranging from immunodeficiency to cancer 
[30, 32–34]. However, despite extensive analysis of 
the role of NFAT proteins in lymphocyte development 
and function, their role in erythropoiesis still need to be 
investigated. Here, by analyzing Il2−/− mice we show that 
an enhanced integrin-cAMP-NFAT signaling axis not only 
downregulated Klf1 expression but also increased the 
apoptosis of Il2−/− erythrocyte precursors. Our findings 
suggest that NFAT hyperactivity is a key mechanism that 
blocks erythrocyte differentiation and promotes anemia 
development in Il2−/− mice, which might also be operative 
in inducing anemia in humans.  
RESULTS
Impaired NFAT activity in Il2-/- immature 
erythrocytes
IL-2 signaling in an all-or-none-dependent 
manner regulates erythropoiesis. This is evident from 
the severely reduced numbers of Ter119+ cells in the 
BM of Il2−/− mice compared to WT and Il2+/- mice 
(Figure 1A). During erythrocyte differentiation in BM, 
CD71+Ter119- erythroid precursor cells differentiate to the 
CD71+Ter119+ stage, where upon further signaling they 
finally develop into CD71-Ter119+ mature erythrocytes 
[35]. As reported earlier, lack of IL-2 signaling resulted 
in a block in erythrocyte differentiation at the transition 
of CD71+Ter119- cells to the CD71+Ter119+ stage [25]. 
As a result, in the BM of Il2−/− mice an accumulation of 
CD71+Ter119- cells and a paucity of Ter119+ cells were 
observed (Figure 1B). To investigate if NFAT proteins 
are involved in this defective erythropoiesis in Il2−/− 
mice, we analysed Nfat expression in erythrocytes. NFAT 
involvement in erythropoiesis has been suggested but their 
exact role is not clear until now [36]. Analysis of BM cells 
revealed a dose-dependent increase in Nfatc1, Nfatc2 and 
Nfatc3 expression in Il2−/− mice compared to littermate 
control mice (Figure 1C). A similar observation in isolated 
BM Ter119+ cells not only revealed erythrocyte-specific 
Nfat expression but also confirmed high Nfat expression 
in Il2−/− mice (Figure 1D). 
At protein levels, immunofluorescence analysis 
revealed NFATc1 proteins in WT immature CD71+Ter119- 
cells (Figure 1E, 1F). Again, enhanced levels of NFATc1 in 
Il2−/− CD71+Ter119- cells compared to WT cells confirmed 
an increased NFAT activity in the immature erythrocytes 
in the absence of IL-2 signaling (Figure 1E, 1F). To further 
substantiate our observation regarding Nfat expression in 
erythrocytes, we analysed the levels of enhanced green 
fluorescent protein (eGFP) expression in CD71+Ter119- 
and Ter119+ (CD71+Ter119+ + CD71-Ter119+) BM cells 
from Nfatc1-eGfp-Bac transgenic (tg) reporter mice [37]. 
Detectable GFP levels in both populations in Nfatc1-
eGfp-Bac tg mice confirmed an erythrocyte-specific 
Nfat expression (Figure 1G, 1H).  Again, CD71+Ter119- 
and Ter119+ cells from Il2−/−Nfatc1-eGfp-Bac tg mice 
revealed higher GFP levels compared to Nfatc1-eGfp-
Bac tg cells, confirming an increased NFAT activity in 
Il2−/− erythrocytes (Figure 1G, 1H). Additionally, GFP 
analysis also revealed a decrease in Nfatc1 expression in 
the more mature Ter119+ cells compared to the immature 
CD71+Ter119- cells, both in the Nfatc1-eGfp-Bac tg and 
Il2−/−Nfatc1-eGfp-Bac tg cells (Figure 1G, 1H) suggesting 
that NFAT activity could influence the transition of 
CD71+Ter119- cells to later stages.
Enhanced integrin-cAMP signaling in Il2-/- 
erythrocytes
We have recently reported an integrin-cAMP 
signaling-mediated regulation of Nfat expression in 
thymocytes and T cells [32]. Involvement of cAMP in 
integrin signaling has been reported previously [38–40]. 
Also, a previous study has reported involvement of 
integrin in erythrocyte development [4]. To investigate 
whether integrin-cAMP signaling also regulates Nfat 
expression in erythrocytes, we analyzed integrin 
expression on erythroid cells. Both at protein and mRNA 
levels, expression of various integrin were detectable 
in WT BM Ter119+ cells (Figure 2A, 2B). Integrin 
expression was highly variable as some integrin (Vcam1, 
Itgb3, Icam2, Icam1 and Sell) were expressed at higher 
level compared to others (Lfa2, Itgb2, Itga6, Itgav, Itgb1, 
Pecam1, Itga4, Itga5 and Selp), (Figure 2B). Interestingly, 
in Il2−/− Ter119+ cells a general and strong increase 
in expression of many integrin was observed (Figure 
2A, 2B). Compared to WT cells, Il2−/− CD71+Ter119+ 
cells showed an increased expression of CD49d, CD2, 
and CD5 molecules (Figure 2A). Additionally, in Il2−/− 
Ter119+ cells an increased expression of other integrin 
(Lfa2, Itgb2, Itga6, Itgav, Itgb1, Pecam1, Itga4, Itga5 
and Selp) (Figure 2B) suggested that enhanced integrin-
cAMP signals might be involved in the upregulated NFAT 
expression in these cells. Supporting this conclusion, 
we observed increased expression of Adcy3 (adenylate 
Oncotarget9634www.impactjournals.com/oncotarget
cyclase 3) and Creb in Il2−/− Ter119+ cells compared to 
WT cells (Figure 2C). Efficient CREB (cAMP-response 
element binding) binding sequences at Nfatc1 promoter, 
as well as Forskolin or cAMP-CREB-mediated Nfatc1 
transcriptional activation has been reported previously [41, 
42]. Our observations suggest that an increased integrin-
cAMP signaling that operates in Il2−/− erythroid cells is 
the reason behind enhanced NFAT activity in these cells.
To explore whether increased cAMP signaling 
influences erythrocyte differentiation, we treated Il2−/− BM 
cells with IL-2 or various cAMP-inducing agents. IL-2 
treatment enhanced the differentiation of CD71+Ter119+ 
cells, whereas increasing cAMP activity by treating cells 
with IBMX; an inhibitor of phosphodiesterase activity, or 
8-CPT-cAMP; a cAMP analog, or with Forskolin reduced 
this differentiation (Figure 2D, 2E). This suggests that the 
increased integrin-cAMP signaling in Il2−/− mice exerts a 
negative influence on erythrocyte differentiation. 
Lack of IL-2 signaling impairs Klf1 expression
The enhanced integrin expression in Il2−/− Ter119+ 
cells suggest that IL-2 signaling in WT cells most 
likely keeps the integrin-cAMP signaling in check and, 
thereby, facilitates differentiation of CD71+Ter119- cells 
to CD71+Ter119+ stage. If this was the case, immature 
erythrocytes should respond to IL-2 signals and, therefore, 
should express the IL-2 receptor (IL-2R). Analysis of IL-
2R components revealed undetectable expression of Il2ra 
(Cd25), very low level of Il2rb (Cd122), and a relatively 
Figure 1: NFAT expression in erythrocytes. (A) Distribution of Ter119+ cells in the BM of Il2−/− mice compared to WT and Il2+/- 
littermate controls. (B) Distribution of CD71+Ter119- and Ter119+ (CD71+Ter119+ + CD71-Ter119+) erythrocyte precursor cells in the BM 
of WT and Il2−/− mice. (C) Expression levels of Nfatc1, Nfatc2 and Nfatc3 mRNA in total BM cells from indicated mice. (D) Nfatc1, Nfatc2 
and Nfatc3 gene expression in isolated BM Ter119+ cells from WT and Il2−/− mice. (E) Immunofluorescence analysis of NFATc1 levels in 
sorted BM CD71+Ter119- cells from WT and Il2−/− mice. DAPI fluorescence indicates nuclear staining. Scale bar, 10 μm. (F) Quantification 
of NFATc1 mean relative fluorescence (MRF) in BM CD71+Ter119- cells from WT (n = 52) and Il2−/− (n = 42) mice. (G) GFP expression 
levels in BM CD71+Ter119- and Ter119+ (CD71+Ter119+ + CD71-Ter119+) cells from Il2−/−Nfatc1-eGfp-Bac tg reporter mice compared to 
WT and Nfatc1-eGfp-Bac tg mice. (H) Quantification of GFP expression levels in BM CD71+Ter119- and Ter119+ (CD71+Ter119+ + CD71-
Ter119+) cells from indicated mice. Data in A and B are cumulative of multiple experiments, and in C-G are representative of 3 independent 
experiments, (n = 4 per group). In (A, B and F) ***p < 0.0001 and in (H) ***p = 0.0004 or 0.0006, one-way ANOVA and unpaired t-test.
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strong expression of Il2rg (Cd132) in WT erythroid cells 
(Figure 3A). Interestingly, compared to WT controls, 
in Il2−/− Ter119+ cells both at mRNA and protein levels 
all three IL-2R components were strongly upregulated 
(Figure 3A, 3B). Intriguingly, WT Ter119+ cells expressed 
higher levels of IL-2Rβ and IL-2Rγ compared to the 
immature CD71+Ter119- cells (Figure 3B). Again, Il2−/− 
Ter119+ cells not only expressed much higher levels of 
IL-2Rβ and IL-2Rγ but also significantly upregulated the 
expression of IL-2Rα, which was not detectable in WT 
Ter119+ cells (Figure 3B). These observations suggest that 
in immature erythrocytes IL-2 signals most likely dampen 
the integrin-cAMP levels to reduce NFAT activity and 
facilitate their differentiation.
To investigate the functional relevance of enhanced 
NFAT activity in Il2−/− erythroid cells, we hypothesized 
that most likely it suppresses Klf1 expression in these 
cells. Analysis of the DNA element 1kb upstream of 
the transcriptional start site of Klf1 gene revealed a 
composite binding site for NFAT (5′-GGAAA/T-3′) and 
STAT5 (5′-TTCNNNGAA-3′) (Figure 3C). Chromatin 
immunoprecipitation analysis revealed a strong NFATc1 
binding at the Klf1 promoter in WT CD71+Ter119- cells 
(Figure 3D). However, we also observed an equally 
strong binding of STAT5 at the Klf1 promoter suggesting 
a possible cooperation between STAT5 and NFATc1 
in regulating Klf1 expression. Accordingly, in reporter 
assays only STAT5 and NFATc1 together induced strong 
Klf1 promoter activity, whereas promoter activity was 
minimal to STAT5 or NFATc1 activity alone (Figure 3E). 
Further, STAT5 and NFATc1-induced Klf1 promoter 
activity was lost when the composite site was mutated 
(ATTCCTTGAA - AGACCTTGAA) (Figure 3F). STAT5 
activity in response to erythropoietin (Epo) signaling has 
Figure 2: Integrin-cAMP signals influence erythrocyte differentiation. (A) Expression levels of CD49d, CD2 and CD5 on 
Ter119+ erythroid cells from WT and Il2−/− mice. (B) Level of mRNA expression of various integrins in Il2−/− Ter119+ cells compared 
to WT mice. (C) Expression of cAMP signaling-related genes Adcy3 and Creb in Il2−/− Ter119+ cells compared to that in WT mice. (D) 
Distribution of erythroid cells based on CD71 and Ter119 expression in WT BM cells cultured for 48 h either in medium only or in the 
presence of IL-2, IBMX, 8-CPT-cAMP or Forskolin (FSK). (E) Quantification of Ter119+ cells at 48 and 72 h of WT BM cell culture in the 
absence or presence of IL-2, IBMX, 8-CPT-cAMP or FSK. Data in (A–C) are representative of three and in (D and E) are representative of 
two independent experiments. Numbers inside the histograms in (A) represent mean fluorescence intensity (MFI) and numbers inside each 
FACS plot in (D) represent percent respective populations. Data in (E) are presented as mean ± s.d., **p = 0.0019, ***p = 0.001, one-way 
ANOVA.
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been reported to critically influence erythrocyte survival 
and differentiation [23, 43]. Interestingly, despite having 
increased NFATc1 levels, in Il2−/− CD71+Ter119- cells a 
strong impairment in NFATc1 binding to Klf1 promoter 
was observed (Figure 3D). This could be due to the 
absence of STAT5 activity in Il2−/− CD71+Ter119- cells 
as they not only are deficient in IL-2 signals, but also 
lack optimal Epo receptor (EpoR) expression [25]. These 
observations suggest that IL-2 signaling is essential 
for optimal Klf1 expression and thereby promotes 
erythropoiesis in the BM.
Enhanced cell death of immature erythrocytes in 
Il2-/- mice 
To investigate whether enhanced NFAT activity 
exerts a negative influence on their survival, we analysed 
cell death in Il2−/− erythroid precursor cells. Annexin V 
analysis revealed a strong increase in apoptosis (50% vs 
15% in BM and 40% vs 8% in spleen) of Il2−/− erythroid 
cells compared to WT mice (Figure 4A). The increased 
cell death in Il2−/− mice was mostly in the CD71+Ter119+ 
and CD71-Ter119+ compartments as cell death in the 
CD71+Ter119- stage was similar to that in WT mouse 
(Figure 4B). These observations suggest that anemia in 
Il2−/− mice is a combinatorial effect of Klf1 dysregulation 
and subsequent apoptosis of immature erythrocytes. 
Agreeing with this, we observed an increase in expression 
of Fasl, a prominent target of NFAT [44, 45], and also of 
Fas, Casp3, Casp8 and Bim in Il2−/− erythroid cells (Figure 
4C). NFAT proteins have been shown to regulate activation-
induced cell death (AICD) of T cells following an immune 
response in a Fas-FasL-dependent manner [46, 47]. Thus, 
enhanced Fas-FasL activity as well as upregulated activity 
of other apoptosis-promoting molecules in IL-2-deficient 
erythroid cells results in increased cell death leading to 
anemia development in Il2−/− mice. 
Ablation of NFAT activity promotes 
erythropoiesis
To investigate which NFAT protein is responsible 
for the defective erythropoiesis in Il2−/− mice, we analyzed 
various Nfat mutant mice.  Analysis of Nfatc2−/− or 
Nfatc3−/− mice revealed comparable numbers of Ter119+ 
cells in BM to that of littermate WT mice (Figure 5A). 
Further analysis for differentiation stages showed 
neither Nfatc2−/− nor Nfatc3−/− mice had any defect at the 
CD71+Ter119+ stage, and they differentiated to CD71-
Ter119+ erythrocytes similar to that in control mice 
(Figure 5B). Even the combined loss of NFATc2 and 
NFATc3 activity (Nfatc2−/−Nfatc3−/− mice) did not impair 
erythropoiesis in the BM (Figure 5B). These observations 
suggest that NFATc1 is the key erythrocyte-specific NFAT 
protein and overactivity of NFATc1 is probably inducing 
the erythropoietic defects and anemia in Il2−/− mice. 
Nfatc1−/− mice are embryonic lethal [48]. Therefore, 
we analyzed Vav-CreNfatc1fl/fl mice, which revealed 
an enhanced erythropoiesis, as they had significantly 
increased Ter119+ population both in BM and spleen 
compared to littermate WT mice (Figure 5C, 5D). This 
was in contrast with the normal erythropoiesis observed 
in Nfatc2−/−, Nfatc3−/− and Nfatc2−/−Nfatc3−/− mice (Figure 
5A, 5B) indicating that manipulation of NFATc1 activity 
can influence erythropoiesis. Also, the increased Ter119+ 
population in Vav-CreNfatc1fl/fl mice was in contrast to the 
severely reduced numbers of Ter119+ cells in Il2−/− mice, 
suggesting that enhanced NFATc1 activity most likely has 
a negative influence on BM erythropoiesis. In line with the 
increase in Ter119+ cells, differentiation of CD71+Ter119- 
cells to Ter119+ stages was enhanced in Vav-CreNfatc1fl/
fl mice compared to WT controls (Figure 5E). Further, 
Vav-CreNfatc1fl/fl Ter119+ cells expressed normal levels of 
Klf1 and Epor, which were suppressed in the Il2−/− mice 
(Figure 5F). 
Next, we analysed if IL-2-deficiency is leading 
to enhanced NFAT activity, treatment with IL-2 should 
reverse this in Il2−/− mice. Interestingly, IL-2 treatment 
effectively downregulated Nfat expression in Il2−/− 
Ter119+ cells (Figure 5G). Simultaneously, a strong 
downregulation in Adcy3, and upregulation in several 
phosphodiesterases (Pde3b, Pde4a, Pde4b, and Pde8a) 
in Il2−/− Ter119+ cells was observed. These observations 
further emphasize that the increased cAMP signaling 
was responsible for the enhanced NFAT activity in Il2−/− 
mice. As a result of downregulation in NFAT activity, 
erythropoiesis in IL-2 treated Il2−/− mice returned to 
normal, as more Ter119+ cells appeared in IL-2 treated 
mice compared to PBS treated controls (Figure 5H). Thus, 
by manipulating cAMP levels, IL-2 signals regulate NFAT 
activity in erythroid cells. 
DISCUSSION
Our observation about Nfat expression in 
erythrocytes suggests they might have a role to play in 
erythropoiesis, and the increased NFAT activity in Il2−/− 
erythroid cells (Figure 1D–1H) could be one of the 
reasons that the Il2−/− mice suffer from severe anemia. We 
have shown previously that IL-2 critically regulates BM 
erythropoiesis in a Treg-dependent manner, and restoration 
of Treg activity or abolition of IFN-γ activity significantly 
reversed anemia in Il2−/− mice [25]. Also, recently we 
have reported that in a Treg-dependent manner IL-2 
signaling plays an indispensable role in the maintenance 
of hematopoietic stem cell (HSC) integrity [49]. 
However, the lack of Treg activity though severely impairs 
BM erythropoiesis, additional factors and signaling 
molecules might be involved in the drastically reduced 
number of RBCs in Il2−/− mice. One possible reason for 
anemia in Il2−/−mice could be increased cell death of the 
differentiating erythrocytes. Our observation regarding 
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Figure 3: Impaired NFATc1 and STAT5 binding at Klf1 promoter in Il2−/− erythrocytes. (A) Expression of Il2ra, Il2rb and Il2rg 
genes in Il2−/− Ter119+ cells compared to WT cells. WT thymocytes and 293T cells were used as positive and negative controls respectively. 
(B) Intracellular expression of CD25 (IL-2Rα), CD122 (IL-2Rβ) and CD132 (IL-2Rγ) in BM CD71+Ter119- and Ter119+ (CD71+Ter119+ 
+ CD71-Ter119+) cells from WT and Il2−/− mice. (C) Nucleotide sequence of 1kb DNA element upstream of the transcriptional start site 
containing the Klf1 gene promoter. The composite NFATc1 (3′-CCTTA-5′: red boxed) and STAT5 (5′-TTCNNNGAA-3′: green boxed) 
binding sites are indicated. Arrows in 5′ and 3′ directions indicate the region amplified in ChIP assays for NFATc1 and STAT5 binding 
to Klf1 promoter. (D) ChIP analysis for NFATc1 and STAT5 binding at the Klf1 promoter region as indicated in (C) in isolated Ter119+ 
cells from WT and Il2−/− mice. ChIP with Akt Abs was used as a negative control. (E) Luciferase reporter assay depicting the influence of 
NFATc1 and STAT5 on Klf1 promoter activity in unstimulated or TPA + Ionomycin (T + I) stimulated 293 HEK cells. (F) Effect of NFATc1 
and STAT5 on mutant Klf1 promoter (TT-GA) activity in unstimulated or TPA + Ionomycin (T + I) stimulated 293 HEK cells. Data in (A, 
B, E and F) are representative of three, and in (D) are representative of two independent experiments. Data in (E and F) are presented as 
mean ± s.d., ns = not significant, and in (E) *p = 0.0178 or 0.0333 and **p = 0.0016, and in (F) *p = 0.0415, paired t-test.
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increased apoptosis of Ter119+ populations in Il2−/− mice 
supports this notion (Figure 4A, 4B). 
Most likely NFAT activity is essential at the 
early stages in the CD71+Ter119- cells and needs to 
be downregulated as the erythrocytes mature. This is 
evident from our analysis of the Nfatc1-eGfp-Bac tg 
reporter mice, where GFP levels were highest in the 
CD71+Ter119- cells but was reduced in the Ter119+ 
cells (Figure 1G, 1H). This probably happens via IL-2 
signaling-mediated downregulation in cAMP levels in 
these cells. Our observations of downregulated Adcy3 and 
upregulated phosphodiesterases expression in IL-2 treated 
Il2−/− mice support this hypothesis (Figure 5G). Under 
this circumstance, Nfat expression was suppressed and 
erythropoiesis in Il2−/− mice was restored (Figure 5G, 5H). 
We have shown previously that integrin-cAMP signaling 
induces Nfat expression in thymocytes and T cells [32]. 
Similar to thymocytes, erythrocytes also express various 
integrin and their levels were strongly upregulated in the 
IL-2-deficient Ter119+ cells (Figure 2A, 2B). Increasing 
intracellular cAMP levels clearly has a negative influence 
on erythrocyte differentiation as fewer Ter119+ cells 
developed in in vitro BM cultures where cAMP levels 
were enhanced (IBMX, 8-CPT-cAMP or FSK treated 
cells) compared to the IL-2-treated cells (Figure 2D, 
2E). This suggests that the developing erythrocytes are 
sensitive to IL-2 signaling.
IL-2 receptor expression in erythrocytes is so far not 
known. However, analysis of ‘ErythronDB’, the database 
containing genes expressed during erythropoiesis, shows 
robust expression of Il2rg in all stages of erythrocyte 
development [50, 51].  The absence of IL-2Rα and low 
levels of IL-2Rβ and IL-2Rγ expression in WT Ter119+ 
cells (Figure 3A, 3B) suggest that in erythrocytes IL-2 
signals most likely are transduced via the intermediate-
affinity IL-2Rβ + IL-2Rγ receptors, similar to that in naïve 
T cells [18].  However, the upregulated expression of IL-
2R components in Il2−/− erythrocytes (Figure 3A, 3B) is 
quite surprising, and we still do not know the mechanism 
behind it. The presence of the composite NFAT and STAT5 
binding sequence at the Klf1 promoter suggests that 
optimal NFAT and STAT5 activity might be an essential 
factor that regulates Klf1 expression in erythrocytes 
(Figure 3C). Enhanced NFAT activity in absence of 
STAT5 activity in Il2−/− erythrocytes failed to induce 
optimal Klf1 expression resulting in a differentiation block 
at the CD71+Ter119- to CD71+Ter119+ transition. Further, 
the induction of Klf1 promoter activity in response to 
combined NFATc1 and STAT5 activity (Figure 3E), and 
the loss of promoter activity when the composite site was 
mutated (Figure 3F) suggests that an optimal activity of 
essential TFs during erythrocyte differentiation stages is 
critical for normal erythropoiesis.  
Our analysis of various Nfat mutant mice suggests 
that NFATc1 activity most likely plays an important role 
in erythrocyte differentiation. Neither single nor combined 
loss of NFATc2 and NFATc3 activity had any influence 
on Ter119+ cell development in the BM (Figure 5A, 5B). 
Figure 4: Enhanced NFAT signaling induces apoptosis in Il2−/− immature erythrocytes. (A) Cell death analysis in BM and 
splenic Ter119+ cells from WT and Il2−/− mice as revealed by Annexin V staining. (B) Quantification of % Annexin V positive cells in BM 
CD71+Ter119-, CD71+Ter119+ and CD71-Ter119+ fractions from WT and Il2−/− mice. (C) Expression of apoptosis-related genes in the BM 
Ter119+ cells from Il2−/− mice compared to WT controls. Data in (A–C) are representative of three independent experiments. Number inside 
each histogram represents percent Annexin V positive population. Data in (B) are presented as mean ± s.d., ns = not significant and *p = 
0.7376 or 0.0141, paired t-test. 
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However, loss of hematopoietic cells-specific NFATc1 
activity clearly induced augmented differentiation of 
CD71+Ter119- cells to the CD71+Ter119+ stage, which 
resulted in the generation of more Ter119+ erythrocytes in 
Vav-CreNfatc1fl/fl mice compared to WT controls (Figure 
5C–5E). This was similar to what has been reported for 
mice deficient in Desert Hedgehog (Dhh) signalling [52]. 
The significant improvement in erythropoiesis in the IL-2 
treated Il2−/− mice (Figure 5H), where upon IL-2 signaling 
Nfat expression was strongly reduced (Figure 5G) also 
supports the point that enhanced NFAT activity is harmful 
for erythrocyte differentiation. 
Altogether, our observations suggest a critical role 
for IL-2 in maintaining steady state RBC number by 
regulating the integrin-cAMP-NFAT signaling axis (Figure 
6). Manipulation of this signaling pathway could open up 
new avenues to modulate erythropoiesis and to prevent 
anemia development. 
MATERIALS AND METHODS
Mice
C57BL/6 wild-type, Il2−/−, Nfatc1-eGfp-Bac tg, Il2−/−
Nfatc1-eGfp-Bac tg, Nfatc1fl/fl, Vav-CreNfatc1fl/fl, Nfatc2−/−, 
Nfatc3−/−, and Nfatc2−/−Nfatc3−/− mice, all on C57BL/6 
background and of 3–8 weeks age unless mentioned 
otherwise were used throughout the study. Animals were 
housed in the central animal facility (ZEMM) of the 
University of Würzburg, according to standard animal 
Figure 5: Reduction in NFATc1 activity facilitates erythropoiesis. (A) Quantification of BM Ter119+ cells in Nfatc2−/− and 
Nfatc3−/− mice compared to littermate control mice. (B) Distribution of erythroid cells based on CD71 and Ter119 expression in the BM of 
Nfatc2−/−, Nfatc3−/− and Nfatc2−/−Nfatc3−/− mice compared to WT mice. (C) Ter119+ cells distribution in the BM of Vav-CreNfatc1fl/fl mice 
compared to littermate control mice. (D) Quantification of percent Ter119+ cells in BM and spleen of Vav-CreNfatc1fl/fl mice compared to 
littermate WT mice. (E) Erythrocyte differentiation profile based on CD71 and Ter119 expression in the spleen of Vav-CreNfatc1fl/fl mice 
compared to WT littermates. (F) Expression of Gata1, Nfe2, Klf1 and Epor genes in BM Ter119+ cells from WT and Vav-CreNfatc1fl/fl 
mice. (G) Nfat and cAMP signaling-related genes expression in BM Ter119+ cells from PBS or IL-2 treated Il2−/− mice. (H) Distribution 
of Ter119+ cells in the BM of PBS or IL-2 treated Il2−/− mice. Data in (A–H) are representative of three or more independent experiments. 
Numbers inside each FACS plot represent percent respective populations. Data in (A and D) are presented as mean ± s.d., ns = not 
significant, in (D) **p = 0.0063 and ***p < 0.0001, one-way ANOVA and paired t-test.
Oncotarget9640www.impactjournals.com/oncotarget
care protocols. All animal experiments were performed 
taking utmost care, and were according to established 
guidelines (approved by the Regierung von Unterfranken, 
Wuerzburg, Permit Number 55.2-2531.01-53/10B). 
Flow cytometry 
For flow cytometry, and Ter119+ BM cell isolation 
all antibodies were purchased either from BD Pharmingen 
or eBioscience. Anti-CD2 (RM2-5), anti-CD5 (53-7.3), 
anti-CD25 (PC61), anti-CD49d (R1-2), anti-CD71 (C2), 
anti-CD122 (TM-b1), anti-CD132 (TUGm2), anti-Ter119 
(TER-119), annexin V and isotype-matched control 
antibodies either directly conjugated with fluorochromes 
or with biotin were used throughout this study. 
Biotinylated antibodies were revealed with secondary 
streptavidin-allophycocyanin or phycoerythrin-Cy5 
(PE-Cy5) antibodies. Flow cytometry and data analysis 
were performed following standard procedure using 
FACSCalibur and FlowJo software. 
Cell isolation and sorting 
For cell isolation and sorting, BM cells from both 
hind limbs were collected and single cell suspension 
was prepared. Ter119+ BM cells were isolated using 
anti-Ter119 microbeads (Miltenyi Biotec) following 
manufacturer’s protocol.  For cell sorting, BM cells were 
incubated with anti-CD71 and anti-Ter119 antibodies. 
CD71+Ter119-, CD71+Ter119+ and CD71-Ter119+ erythroid 
cells were sorted by using a FACSAria (BD Biosciences) 
flow cytometer. 
Figure 6: Model showing the role of IL-2 in maintaining BM erythropoiesis. (A) IL-2 signals are essential to lower the 
integrin-cAMP-NFAT signaling, and in facilitating optimal KLF1 and EpoR expression, which results in normal erythropoiesis in the BM. 
(B) Deficiency in IL-2 or of any component of IL-2 signaling pathway leads to upregulated integrin-cAMP-NFAT signaling as well as 
suppressed Klf1 and Epor expression. Both these defects combinedly result in enhanced cell death of immature erythrocytes leading to the 
development of severe anemia in IL-2 signaling-deficient mice. Grey dashed arrow represents lack of Epo signaling.
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Immunofluorescence staining 
Sorted CD71+Ter119- BM cells from WT or Il2−/− mice 
were immunostained with NFATc1 (Santa Cruz, sc14034) 
antibodies following previously published protocol [30]. 
DAPI was used to confirm nuclear staining.
Intracellular staining
For intracellular CD25 (IL-2Rα), CD122 (IL-2Rβ) and 
CD132 (IL-2Rγ) staining, 5 × 106 freshly prepared BM cells 
from WT and Il2−/− mice were used. Cells were first surface 
stained for CD71 and Ter119 followed by intracellular CD25, 
CD122 and CD132 staining according to eBioscience Foxp3 
staining protocol. IL-2 receptors expression in erythroid cells 
was analyzed by gating on CD71+Ter119-, CD71+Ter119+ 
and CD71-Ter119+ erythroid cells. 
Cell death analysis
1 × 106 freshly isolated WT or Il2−/− BM and spleen 
cells were used to evaluate apoptosis of total Ter119+ 
cells, or of gated CD71+Ter119-, CD71+Ter119+ and 
CD71-Ter119+ erythroid cells. BM cells were stained 
for CD71 and Ter119 and subsequently, live or dead cell 
discrimination was performed with annexin V staining 
following manufacturer’s protocol (BD Biosciences).
Chromatin immunoprecipitation
5–8 × 106 WT or Il2−/− BM CD71+Ter119+ cells were 
used for each ChIP assay following the Miltenyi Biotec ChIP 
protocol. 8–10 µg of NFATc1 (Santa Cruz; sc-7294), pSTAT5 
(NEB; 9314), and Akt (NEB; 9272) antibodies were used 
for immunoprecipitation. DNA fragments were purified and 
used to amplify the Klf1 promoter region bound to NFATc1 
or STAT5. Primers used to amplify the Klf1 promoter region 
are mentioned in the Supplementary Table 1. 
In vivo injections
6 weeks old male and female Il2-/- mice were 
injected on every alternate day with 1 µg recombinant 
murine IL-2 (rmIL-2, Peprotech) or an equal volume of 
PBS intraperitoneally for two consecutive weeks. Four 
days after getting the last injection, mice were analyzed 
to study the effects of IL-2 on erythropoiesis in the BM. 
In vitro culture assay
3 × 106 freshly isolated WT BM cells were either 
cultured in RPMI-1640 medium supplemented with 10% 
FCS only, or in presence of IL-2 (1 µg), IBMX (0.5 mM), 
8-CPT-cAMP (50 µM) or Forskolin (50 µM). 48 or 72 h 
later cells were analyzed to investigate the influence of 
IL-2 or various cAMP-inducing agents on erythrocyte 
differentiation.
Semiquantitative RT-PCR
Total BM cells or magnetically isolated Ter119+ 
cells from WT or Il2−/− mice were used to synthesize 
cDNA using Miltenyi Biotec cDNA synthesis kit and 
protocol. Semiquantitative RT-PCR was performed to 
investigate the expression of indicated genes. Primer 
sequences are available in the supplementary information 
online.
Luciferase reporter assays
The 1007bp Klf1 promoter fragment was generated 
by amplification from murine genomic DNA (chr8: 
87424731-87426061) using following primers: Fw.5´-
AACTCGAGCATCTATCATGGGGTCCCGC-3´ and 
Rev.5´-TTAAGCTTGGGCTATGAGGCTAGGAA
AG-3´. The blunt ended left (XhoI) and right (HindIII) 
arms were cloned into the corresponding XhoI and 
HindIII sites of pGL3 basic vector. 50 ng of murine Klf1 
luciferase reporter construct containing the 1007bp DNA 
fragment spanning the promoter region (-960 to +47 bp) 
was co-transfected along with 500 ng control vectors, 
or expression vectors for a constitutively active STAT5 
(STAT5ca) or NFATc1 (Nc1) alone, or with both STAT5 
and NFATc1 into 293 HEK cells by polyethylenimine 
(PEI) (St. Louis, Missouri, USA) transfection method. 
36 h post-transfection cells were left unstimulated or 
stimulated with PMA plus Ionomycin (100 ng/ml each, 
Calbiochem) for 12 h. Afterwards, luciferase activity 
representing the Klf1 promoter transactivation was 
measured using a MicroLumat LB 96P (EG&G Berthold) 
luminometer. For mutant Klf1 promoter construct, 
mutations in the composite STAT5-NFAT binding site 
(TT-GA) were introduced by site directed mutagenesis and 
promoter activity was assessed in response to STAT5 and 
NFATc1 activity. 
Statistics
Data are presented as mean ± s.d. Statistical 
significance was assessed using Student’s t-test for 
comparison between two groups and ANOVA for 
differences between groups.
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